Skip to content
OpenCapital
Get started

Opus Genetics IRD Utilized Federal Research Credit Carryforwards

Utilized Federal Research Credit Carryforwards at other companies

Syntec Optics Holdings, Inc. logo
Syntec Optics Holdings, Inc.OPTX
$740.87K+8.2%
HTF
Heartflow, Inc. Common StockHTFL
$7.63M+7.3%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$6.91M-4.9%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$5.37M+74.4%
Ondas, Inc. logo
Ondas, Inc. ONDS
$1.17M+55.3%
HRO
HarrowHROW
$4.79M+111%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M—
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×—
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept ird:UtilizedFederalResearchCreditCarryforwards.

The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's utilized federal research credit carryforwards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's utilized federal research credit carryforwards?
Opus Genetics (IRD) reported utilized federal research credit carryforwards of $0 in Q4 2025.
What is the long-term trend for Opus Genetics's utilized federal research credit carryforwards?
Over 2 years (2023 to 2025), Opus Genetics's utilized federal research credit carryforwards has grown at a -100.0% compound annual growth rate (CAGR), from $26K to $0.
What does utilized federal research credit carryforwards mean?
This metric tracks the amount of federal research and development tax credits that have been applied to reduce current income tax obligations. These credits are generated by qualifying R&D expenditures and are essential for clinical-stage biopharmaceutical companies managing high burn rates. It serves as an indicator of the company's ability to monetize innovation-related tax incentives to improve cash flow.